The Federal Institute for Drugs and Medical Devices, the German regulatory authority, has approved Helix BioPharma's clinical trial application for a European Phase III efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.
Subscribe to our email newsletter
The company requires a strategic partner, additional funding, and interferon alpha-2b raw material support so as to begin any such trial.
Helix, a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, at present do not have an estimated timeline for initiation of such trial.